- Home
- CCI vs TAK Comparison
CCI vs TAK Comparison
Compare CCI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCI
- TAK
- Stock Information
- Founded
- CCI 1994
- TAK 1781
- Country
- CCI United States
- TAK Japan
- Employees
- CCI N/A
- TAK N/A
- Industry
- CCI Real Estate Investment Trusts
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- CCI Real Estate
- TAK Health Care
- Exchange
- CCI Nasdaq
- TAK Nasdaq
- Market Cap
- CCI 43.5B
- TAK 45.8B
- IPO Year
- CCI 1998
- TAK N/A
- Fundamental
- Price
- CCI $100.19
- TAK $14.76
- Analyst Decision
- CCI Buy
- TAK
- Analyst Count
- CCI 20
- TAK 0
- Target Price
- CCI $116.95
- TAK N/A
- AVG Volume (30 Days)
- CCI 2.9M
- TAK 1.9M
- Earning Date
- CCI 07-16-2025
- TAK 07-30-2025
- Dividend Yield
- CCI 5.76%
- TAK 4.01%
- EPS Growth
- CCI N/A
- TAK N/A
- EPS
- CCI N/A
- TAK 0.45
- Revenue
- CCI $6,515,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- CCI N/A
- TAK $1.01
- Revenue Next Year
- CCI $3.08
- TAK $1.04
- P/E Ratio
- CCI N/A
- TAK $63.71
- Revenue Growth
- CCI 3.05
- TAK 7.45
- 52 Week Low
- CCI $84.20
- TAK $12.58
- 52 Week High
- CCI $120.92
- TAK $15.43
- Technical
- Relative Strength Index (RSI)
- CCI 50.17
- TAK 46.62
- Support Level
- CCI $98.03
- TAK $14.86
- Resistance Level
- CCI $100.38
- TAK $15.42
- Average True Range (ATR)
- CCI 1.56
- TAK 0.14
- MACD
- CCI 0.06
- TAK -0.03
- Stochastic Oscillator
- CCI 75.66
- TAK 9.47
About CCI Crown Castle Inc.
Crown Castle owns and leases roughly 40,000 cell towers in the United States. It also owns more than 90,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. Crown Castle's towers and fiber are predominantly in the largest US cities. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers. Crown Castle operates as a real estate investment trust. It has announced plans to divest its fiber business, which should be finalized in 2026. After that, Crown will be a stand-alone tower operator.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.